Asenapine (USAN rINNM and BANM; trade names Saphris (AU US) Sycrest (EU UK)) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19 2007 merger with Organon International. Development of the drug through Phase III trials began while Organon was still a part of Akzo Nobel.
This page contains content from the copyrighted Wikipedia article "Asenapine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
